Table 4.
Variables associated with TE ≥ 7.1kPa/TE < 7.1kPa in HIV monoinfected patients.
| Characteristics | TE ≥ 7.1 kPa n = 7 | TE < 7.1 kPa n = 19 | Unadjusted P PR (95% Cl)a univariate | |
|---|---|---|---|---|
| Demographics | ||||
| Age (years) | 50 ± 6 | 51 ± 12 | 0.99 (0.94–1.04) | 0.694 |
| Sex, male (%) | 5 (71.4) | 14 (73.7) | 0.92 (0.23–3.80) | 0.908 |
| BMI (Kg/m2)* | 27.4 (24.4–32.5) | 26.8 (24.7–29.3) | 1.07 (0.95–1.19) | 0.273 |
| Physical activity§ (%) | 4 (57.1) | 4 (21.1) | 3.00 (0.86–10.4) | 0.083 |
| Hypertension (%) | 2 (28.6) | 2 (10.5) | 2.20 (0.63–7.65) | 0.215 |
| IFG/Diabetes (%) | 4 (57.1) | 9 (47.4) | 1.33 (0.37–4.82) | 0.661 |
| Metabolic syndrome (%) | 5 (71.4) | 5 (26.3) | 4.00 (0.95–16.8) | 0.059 |
| HIV | ||||
| Time since HIV (years)* | 20 (9–22) | 16 (6–21) | 1.05 (0.95–1.17) | 0.353 |
| Time on ART (years)* | 14 (7–22) | 14 (6–16) | 1.05 (0.95–1.15) | 0.367 |
| CD4 count (cells/µL)* | 698 (541–828) | 607 (450–879) | 1.00 (1.00–1.00) | 0.499 |
| Labs | ||||
| Triglycerides (mg/dL)* | 240 (219–438) | 175 (125–228) | 1.00 (1.00–1.10) | 0.037 |
| Total cholesterol (mg/dL) | 190 ± 36 | 185 ± 36 | 1.00 (1.00–1.02) | 0.773 |
| LDL cholesterol (mg/dL) | 88 ± 27 | 100 ± 26 | 0.99 (0.96–1.01) | 0.328 |
| HDL cholesterol (mg/dL)* | 36 (31–53) | 45 (37–51) | 0.97 (1.00–1.05) | 0.481 |
| AST (U/L)* | 26 (20–35) | 24 (21–29) | 1.02 (0.95–1.10) | 0.566 |
| ALT (U/L)* | 44 (28–73) | 27 (20–40) | 1.01 (0.99–1.04) | 0.302 |
| Total bilirubin (mg/dL)* | 0.7 (0.4–2.2) | 0.7 (0.3–2.5) | 0.98 (0.56–1.60) | 0.938 |
| Noninvasive markers | ||||
| APRI score* | 0.255 (0.149–0.447) | 0.274 (0.201–0.401) | 1.45 (0.15–14.34) | 0.752 |
| FIB4 score* | 0.98 (0.66–2.64) | 0.90 (0.76–1.0) | 1.46 (1.15–1.86) | 0.002 |
| Transient elastography | ||||
| CAP* | 360 (320–364) | 272 (246–294) | 1.02 (1.00–1.04) | 0.049 |
| CAP ≥ 238 (dB/m) (%) | 4 (57.1) | 16 (84.2) | 0.60 (1.00–3.72) | 0.583 |
Abbreviations: TE, transient elastography; BMI, body mass index; IFG, impaired fasting glucose; ART, antiretroviral therapy; LDL, low density lipoprotein; HDL, high density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; FIB-4, fibrosis-4; APRI, AST to platelet ratio index; CAP, controlled attenuation parameter; PR, prevalence ration; CI, confidence interval.
Median (IQR)*.
§Physical activity was considered above 3 times a week.
aPrevalence ratio and confidence intervals were estimated using Poisson regression.